Corvus Pharmaceuticals Inc (CRVS) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results

Protocol finalized for soquelitinib (CPI-818) Phase 3 registrational clinical trial in peripheral T cell...

Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition

BURLINGAME, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a...

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases

Data demonstrated soquelitinib was active in six inflammatory/immune disease models and provides rationale for...

Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023

BURLINGAME, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a...

Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA

Plans to initiate soquelitinib potentially registrational Phase 3 clinical trial in Q1 2024 Company to host...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results

Interim Phase 1/1b clinical results with soquelitinib and published clinical studies on mechanism of action...

Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023

BURLINGAME, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a...

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818)

 Data highlights the differentiated mechanism of action of soquelitinib to enhance anti-tumor immune response...

Corvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference

Preclinical data highlights ciforadenant’s mechanism of action and synergy with immune checkpoint inhibitors...